Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

In a small percentage of patients, T-cell accumulation is so extensive that disfiguring nodules and tumors develop (see Figure 4). As the tumors grow they may ulcerate and lead to considerable ...

A new systematic review reveals promising results for oncolytic viral therapy in treating nonmelanoma skin cancers and ...

Investigators found that denileukin diftitox, which targets the interleukin-2 receptor, achieves objective response rates in 44% of patients with cutaneous T-cell lymphoma, with a median duration ...

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

It is being tested in clinical trials for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma. The FDA’s ...

"Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial" was originally created and published by ...

utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active ...

The company is actively progressing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Other candidates in ...

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on ...